Standard Grant: Studying the Transformation of Cancer Prevention Technologies

该奖项支持一个研究项目，该项目研究目前已知与人类乳头瘤病毒（HPV）有因果关系的癌症的领先预防技术的社会技术景观。这项研究的重点是制药业，疫苗和dna检测工具市场的基本原理，以及由此产生的健康和疾病的政治和道德经济干预。这项研究的结果将有可能塑造跨学科科学和技术研究的概念框架，这些研究旨在了解生物医学和公共卫生变革的机制及其对人类健康和福祉的影响；它们还将有潜力通过与临床和公共卫生受众以行动为导向的接触，塑造公共卫生和临床行为者对癌症预防做法的看法和做法。通过与政策制定者、临床医生和制药开发商建立反馈循环，PI致力于确保那些参与癌症预防挑战的人，特别是公共卫生癌症差异，参与这些发现，考虑如何最好地减少癌症负担。这一研究项目旨在了解两套商业产品（人乳头瘤病毒疫苗和人乳头瘤病毒DNA检测）的开发如何影响健康、风险和疾病的意义和分布，以及如何提供减少癌症的公共卫生办法。它有三个核心目标。首先，它将记录构成HPV和HPV-癌症预防转型景观的社会技术轨迹，重点是基于DNA的预防和筛查工具，HPV疫苗和HPV检测，以及它们的制药工业材料。其次，它将分析在不断变化的公共卫生格局中设想的生物主体和公众的种类，以及从这一愿景中想象和实现的临床和公共卫生服务的分类。最后，它将评估确保技术采用和通过减少人乳头瘤病毒和人乳头瘤病毒相关癌症影响健康和疾病公平分配的机会和挑战。总体目标是促进越来越多的关于健康和疾病的生物医学化和药物化的跨学科研究；它将提供重要的见解，关于药品参与塑造卫生保健的方式，无论是作为一种公共产品还是商品，为一些人带来健康，而将其他人排除在潜在利益之外。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

This award supports a research project that studies the socio-technical landscape of leading prevention technologies for cancers now known to be causally related to the human papillomavirus, HPV. The study focuses on pharmaceutical industries, the rationale embedded in markets for vaccines and DNA-testing tools, and the resulting interventions within a political and moral economy of health and illness. The results of this study will have the potential to shape conceptual frameworks in interdisciplinary science and technology studies that seek to understand the mechanisms of biomedical and public health transformations and their impacts on human health and wellbeing; they will also have the potential to shape how public health and clinical actors think about and approach cancer prevention practices through action-oriented engagement with clinical and public health audiences. By creating a feedback loop with policy-makers, clinicians, and pharmaceutical developers, the PI seeks to work toward ensuring that those engaging in the challenge of cancer prevention and especially, public health cancer disparities, engage with these findings to consider how best to reduce cancer burdens.This research project seeks to understand how the development of two sets of commercial products, HPV vaccines and HPV DNA tests, is shaping the meaning and distribution of health, risk and disease and the delivery of public health approaches to reducing cancer. It has three core objectives. First, it will document the socio-technical trajectories that constitute the transforming landscape of HPV and HPV-cancer prevention, with a focus on DNA based prevention and screening tools, HPV Vaccines and HPV Tests, and their pharmaceutical industry materials. Second, it will analyze the kinds of biological subjects and publics that are envisioned in the transforming public health landscape, and what taxonomies of clinical and public health services are imagined and realized from this vision. Finally, it will assess the opportunities and challenges to both ensure technological adoption and to impact equitable distribution of health and illness via the reduction of HPV and HPV-related cancers. The overarching goal is to contribute to the growing body of interdisciplinary research on the biomedicalization and pharmaceuticalization of health and illness; it will provide important insights concerning the ways pharmaceuticals participate in shaping health care either as a public good or commodity, generating health for some while leaving others outside of potential benefits.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.